Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 402,126 shares, an increase of 22,315.1% from the June 30th total of 1,794 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 75,614 shares, the short-interest ratio is presently 5.3 days.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded Raia Drogasil to a “hold” rating in a research note on Thursday, April 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.
Read Our Latest Stock Analysis on Raia Drogasil
Raia Drogasil Price Performance
About Raia Drogasil
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
See Also
- Five stocks we like better than Raia Drogasil
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
